Page History

...

We recently received this request: SARS CoV-2 stimulated gamma interferon [Presence] in Blood (https://loinc.org/95971-8/ --- SARS CoV-2 stimulated gamma interferon [Presence] in Blood). We also recieved received requests for the following LOINC codes: 95974-2, 95972-6, and 95973-4. Upon further research on all 4 LOINC codes, they are referring to the IFNg Response AssayIFN-y Release Assay (IGRA), which has been modeled in the LB domain in the both TB-TAUG.TAUGs V1 and V2.

TB-TAUG v2.0 modeling looks like the following - The IFNG Response test toward M. Tuberculosis is modeled in the LB domain, in the TB-TAUG as the following:

ELISA:

ELISPOT:

Image Modified

TB-TAUG v1.0 modeling looks like the following - 

Image Added

There are several concerns with this modeling:

1. There are two ways of modeling Interferon Gamma Release Assay based on TB-TAUG V1 and V2, does V2 modeling replace V1 modeling? Are they modeling the same thing?
   • Email sent to Jon to see if V2 model is intended to replace V1 model.
   • Email from Jon 2022-07-07: I was indeed part of the team but have no recollection of this example or any of the discussions around how it evolved. However, I think it’s safest to go with TBv2; it must have been updated for a reason. I would deprecate the original TESTCD, especially if you’ve already been denying additional requests for tests following that same structure. 
2. Where do you show that this challenge assay is done against M. Tuberculosis (or any microbe of interest, like SARS-CoV-2), where do you map M. TbTuberculosis? - NHOID is NOT appropriate and should NOT be used here because in this case, the subject of study is NOT the Mycobacterium tuberculosis itself but whether someone has been previously exposed to M. Tuberculosis, by examining whether there is heightened Interferon-gamma activation. A positive result does not mean the person is currently infected with Mycobacterium tuberculosis, it may mean that the person had been previously infected by, or vaccinated against M. Tuberculosis. NHOID is used when you know the microorganism or a reference strain is present in the testing sample. M. Tuberculosis is mapped to ISCNDAGT to indicate that the stimulating agents are TB antigens.

   1. Info
      title When should NHOID be used?
      NHOID, defined by the Non-host Organism Identifiers (OI) domain, should be used to map microorganisms that have been either experimentally determined in the course of a study or are previously known (e.g., lab strains used as reference in the study). In other words, NHOID is used when the study subject is the microorganism, and when the microorganism is present in the testing sample. In vaccine efficacy studies, a subject’s post-immunization sera is often incubated with a microbial strain of interest, where the functional capacities of the vaccine-induced antibodies are measured through whether the antibodies can effectively stop (from infection), neutralize, and kill the study microorganism of interest, in vitro. Examples of such tests include microneutralization, hemagglutination inhibition, and opsonophagocytic-killing assays. These are tests which measure the direct effect of the antimicrobial antibodies on the microorganism; therefore, said microorganism is the study subject and should be mapped to NHOID. Tests that measure and quantify a subject's cellular and humoral immune responses to a microorganism or a vaccination agent—such as measurements of activated cytokine- or antibody–secreting cells, or cytokine response assays (e.g., interferon gamma response test)—are biological measurements about the human subject. Because these are not assessments about the microorganism itself, NHOID should not be used.

   CP domain has developed a new standard variable called Test Condition Agent/CNDAGT (CP Specification), which is used to represent stimulating agents, like the values in ASSYAG above, should this variable be added to LB, or IS?  StatuscolourGreentitleTeam agrees
3. Lastly, Interferon-Gamma Response Assay is a classic immunological test, is it correct to map this to the LB domain?
   
   1. Can we model this in the IS domain, see example dataset below. Yes -

      Status
      colour Green title Team Agrees

   2. If we model this test in IS, how do we distinguish it from the INFg test in lab. If we are running a routine lab test looking for IFNg levels it goes to LB. If we are running IFNg challenge/response test toward a specific, known microorganism then it goes to IS, you will also need to use the ISCNDAGT variable to house the challenge agent name. Yes-

      Status
      colour Green title Team Agrees

If we were to model this in IS:

1. • Map to NHOID.
     
2. Interferon-Gamma Release Assay (IGRA) is a classic immunological test, is it correct to map this to the LB domain as per the TB TAUGs? What recommendations do we give to our users in the future when we see a request such as: SARS-CoV-2 stimulated gamma interferon, https://loinc.org/95971-8/?
   
   • Model in IS, if you need to report the detailed changes in the actual levels of IFN-y or number of IFN-y secreting cells, the stimulating and control agents used in the assay, and a "summary interpretation" result of positive, negative, or indeterminate, etc. In this case, you are testing and recording the explicit changes in the subject/host's IFN-y release immune response, and this belongs in the IS domain. A derived MB record may be created to show that M. Tuberculosis is identified/detected based on the interpretation of the IS dataset.
   • or...
   • Model and report in MB ONLY, if you do NOT care or the lab does not provide you with actual details and results of the subject/host's IFN-y levels related changes. In this case, you are doing a microbial detection/identification test based on the interpretation (MBTSTDTL) of the INTERFERON GAMMA RELEASE ASSAY (MBMETHOD), see here: https://loinc.org/71773-6/.
3. The ELISPOT LB example in the TB-TAUG V2 has an error, the unit is reported in SFC/10^6 PBMC so you are counting the number of cells that secrete IFN-y. The example had a LBTEST = interferon gamma, this is wrong, the test should be measured in Cells, and should be changed to ISTEST = Cytokine-secreting Cells, where ISMSCBCE = Interferon Gamma.

TB-TAUG v2.0 Remodel in the IS domain

Model in IS, if you need to report changes in the actual level of IFN-y or number of IFN-y secreting cells, the stimulating and control agents used in the assay, and a "summary interpretation" result of positive, negative, or indeterminate, etc. In this case, you are testing and recording the explicit changes in the IFN-y release immune response, and this belong in the IS domain.

Example 1: Measure INF-y using T-Cell ELISPOTT-Cell ELISPOT:

PERIPHERAL BLOOD MONONUCLEAR CELLS